S&P 500   5,150.83 (-0.93%)
DOW   38,140.93 (-0.83%)
QQQ   440.01 (-1.20%)
AAPL   176.60 (+0.89%)
MSFT   423.13 (-1.12%)
META   516.06 (-1.36%)
GOOGL   158.32 (-0.68%)
AMZN   187.17 (-0.99%)
TSLA   172.28 (-1.33%)
NVDA   890.31 (-1.75%)
AMD   163.67 (-4.01%)
NIO   4.13 (-7.40%)
BABA   72.43 (-3.23%)
T   16.41 (-0.06%)
F   12.69 (-2.68%)
MU   123.17 (-3.40%)
GE   153.57 (-2.43%)
CGC   8.02 (-1.60%)
DIS   114.43 (-2.32%)
AMC   2.71 (-3.21%)
PFE   26.13 (-0.80%)
PYPL   65.27 (-0.81%)
XOM   122.96 (+0.96%)
S&P 500   5,150.83 (-0.93%)
DOW   38,140.93 (-0.83%)
QQQ   440.01 (-1.20%)
AAPL   176.60 (+0.89%)
MSFT   423.13 (-1.12%)
META   516.06 (-1.36%)
GOOGL   158.32 (-0.68%)
AMZN   187.17 (-0.99%)
TSLA   172.28 (-1.33%)
NVDA   890.31 (-1.75%)
AMD   163.67 (-4.01%)
NIO   4.13 (-7.40%)
BABA   72.43 (-3.23%)
T   16.41 (-0.06%)
F   12.69 (-2.68%)
MU   123.17 (-3.40%)
GE   153.57 (-2.43%)
CGC   8.02 (-1.60%)
DIS   114.43 (-2.32%)
AMC   2.71 (-3.21%)
PFE   26.13 (-0.80%)
PYPL   65.27 (-0.81%)
XOM   122.96 (+0.96%)
S&P 500   5,150.83 (-0.93%)
DOW   38,140.93 (-0.83%)
QQQ   440.01 (-1.20%)
AAPL   176.60 (+0.89%)
MSFT   423.13 (-1.12%)
META   516.06 (-1.36%)
GOOGL   158.32 (-0.68%)
AMZN   187.17 (-0.99%)
TSLA   172.28 (-1.33%)
NVDA   890.31 (-1.75%)
AMD   163.67 (-4.01%)
NIO   4.13 (-7.40%)
BABA   72.43 (-3.23%)
T   16.41 (-0.06%)
F   12.69 (-2.68%)
MU   123.17 (-3.40%)
GE   153.57 (-2.43%)
CGC   8.02 (-1.60%)
DIS   114.43 (-2.32%)
AMC   2.71 (-3.21%)
PFE   26.13 (-0.80%)
PYPL   65.27 (-0.81%)
XOM   122.96 (+0.96%)
S&P 500   5,150.83 (-0.93%)
DOW   38,140.93 (-0.83%)
QQQ   440.01 (-1.20%)
AAPL   176.60 (+0.89%)
MSFT   423.13 (-1.12%)
META   516.06 (-1.36%)
GOOGL   158.32 (-0.68%)
AMZN   187.17 (-0.99%)
TSLA   172.28 (-1.33%)
NVDA   890.31 (-1.75%)
AMD   163.67 (-4.01%)
NIO   4.13 (-7.40%)
BABA   72.43 (-3.23%)
T   16.41 (-0.06%)
F   12.69 (-2.68%)
MU   123.17 (-3.40%)
GE   153.57 (-2.43%)
CGC   8.02 (-1.60%)
DIS   114.43 (-2.32%)
AMC   2.71 (-3.21%)
PFE   26.13 (-0.80%)
PYPL   65.27 (-0.81%)
XOM   122.96 (+0.96%)
NASDAQ:MBIO

Mustang Bio (MBIO) Stock Price, News & Analysis

$0.52
-0.03 (-4.97%)
(As of 11:15 AM ET)
Today's Range
$0.52
$0.55
50-Day Range
$0.52
$1.39
52-Week Range
$0.51
$8.17
Volume
53,433 shs
Average Volume
161,990 shs
Market Capitalization
$5.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.25

Mustang Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3,217.3% Upside
$17.25 Price Target
Short Interest
Healthy
2.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Mustang Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.36 out of 5 stars

MBIO stock logo

About Mustang Bio Stock (NASDAQ:MBIO)

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

MBIO Stock Price History

MBIO Stock News Headlines

SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
Mustang Bio Inc (MBIO)
SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
Mustang Bio Inc MBIO
MBIO Mustang Bio, Inc.
What 4 Analyst Ratings Have To Say About Mustang Bio
H.C. Wainwright Sticks to Their Buy Rating for Mustang Bio (MBIO)
MBIO - Mustang Bio, Inc.
H.C. Wainwright Remains a Buy on Mustang Bio (MBIO)
BTIG Keeps Their Buy Rating on Mustang Bio (MBIO)
See More Headlines
Receive MBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
4/12/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MBIO
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.25
High Stock Price Target
$25.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+3,052.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-51,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.01 per share

Miscellaneous

Free Float
10,172,000
Market Cap
$5.69 million
Optionable
Not Optionable
Beta
1.58
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael S. Weiss Esq. (Age 58)
    Executive Chairman
    Comp: $60k
  • Dr. Manuel Litchman M.D. (Age 70)
    President, CEO & Director
    Comp: $480.79k
  • Mr. James B. Murphy (Age 67)
    Interim Chief Financial Officer
  • Mr. Peter Carney (Age 37)
    Controller & Interim Chief Accounting Officer
  • Mr. Matthew Wein J.D.
    VP & General Counsel
  • Ms. Debra Manning SPHR
    Senior VP & Head of Human Resources
  • Ms. Lynn E. Bayless M.S.
    VP & Head of Regulatory Affairs
  • Dr. Bruce Dezube M.D.
    Senior VP & Head of Clinical Development
  • Mr. Greg Furrow M.S.
    Chief Quality Officer
  • Mr. Richard Bodmer M.S.
    Head of CMC Development

MBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Mustang Bio stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBIO shares.
View MBIO analyst ratings
or view top-rated stocks.

What is Mustang Bio's stock price target for 2024?

3 brokers have issued 1-year price objectives for Mustang Bio's stock. Their MBIO share price targets range from $10.00 to $25.00. On average, they anticipate the company's share price to reach $17.25 in the next twelve months. This suggests a possible upside of 3,217.3% from the stock's current price.
View analysts price targets for MBIO
or view top-rated stocks among Wall Street analysts.

How have MBIO shares performed in 2024?

Mustang Bio's stock was trading at $1.35 on January 1st, 2024. Since then, MBIO shares have decreased by 61.5% and is now trading at $0.52.
View the best growth stocks for 2024 here
.

Are investors shorting Mustang Bio?

Mustang Bio saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 178,000 shares, a decrease of 54.2% from the March 15th total of 389,000 shares. Based on an average trading volume of 154,600 shares, the days-to-cover ratio is currently 1.2 days. Approximately 2.4% of the company's shares are short sold.
View Mustang Bio's Short Interest
.

When is Mustang Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our MBIO earnings forecast
.

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) issued its quarterly earnings results on Monday, March, 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.68) by $0.97.

When did Mustang Bio's stock split?

Mustang Bio's stock reverse split on Tuesday, April 4th 2023. The 1-15 reverse split was announced on Tuesday, April 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Mustang Bio own?
How do I buy shares of Mustang Bio?

Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MBIO) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners